Shares of Intuitive Surgical (NSDQ:ISRG) got a pre-market bump today after the robot-assisted surgery pioneer posted third-quarter results that beat the consensus forecast, despite lower profits, and upped its outlook on procedure growth for the year. Sunnyvale, Calif.-based Intuitive posted profits of $292.5 million, or $2.45 per share, on sales of $920.9 million for the three […]
Wall Street Beat
Getinge’s Atrium Medical deals biosurg biz to SeCQure Surgical parent
Getinge (PINK:GETI B) subsidiary Atrium Medical said today that it agreed to deal its biosurgery business to the parent company of SeCQure Surgical for an undisclosed amount. Göteborg, Sweden-based Getinge acquired the biosurgery unit, which makes soft tissue reinforcement devices, in the $680 million deal for Atrium back in 2011. Today Getinge said it agreed to sell the business, which […]
Evolent Health prices $150m convertible debt offering
Evolent Health (NYSE:EVH) yesterday priced an upcoming $150 million convertible debt offering. The Arlington, Va.-based company said it plans to offer 1.5% convertible senior notes due 2025 in the offering, with a 30-day option to initial purchasers to acquire an additional $22.5 million aggregate principal amount of notes. Interest on the notes is payable semiannually in […]
Abbott CEO on Libre: ‘We’re just getting started’
Abbott (NYSE:ABT) posted its third quarter financial results yesterday, meeting its own forecast and the consensus set by analysts on Wall Street. The healthcare giant also narrowed its earnings outlook for the rest of the year. Abbott noted particularly high gains in revenue for its medical device division – sales were up 8.4% to $2.82 billion, in part […]
Fresenius plunges on missed prelims, guidance cut
Fresenius (NYSE:FMS) shares closed down some 17% yesterday after it cut its outlook for the rest of the year on lower-than-expected third-quarter results. The German dialysis giant released preliminary figures for the three months ended Sept. 30, saying it expects to report profits of €285 million on sales of €4.06 billion. Analysts were looking for sales of €4.12 billion. […]
Anthem, Novo Nordisk team up for real-world diabetes drug study
Anthem’s outcomes research unit, HealthCore, and Novo Nordisk (NYSE:NVO) have joined forces to study Novo Nordisk’s semaglutide GLP-1 receptor agonist in people with Type 2 diabetes. The real-world trial is designed to compare the long-term effectiveness of the drug, also known as Ozempic, against 40 other medications among 2,250 adults with Type 2 diabetes. Get the full story […]
Gauss Surgical raises $20m in Series C
Gauss Surgical said today it raised $20 million in a Series C round of financing to support its Triton surgical blood loss monitoring platform. The Los Altos, Calif.-based company’s Triton device and software are designed to help reduce unnecessary transfusions by scanning surgical sponges and blood bearing canisters while image-processing algorithms estimate the amount of […]
Si-Bone prices upsized $108m IPO
Si-Bone yesterday priced its initial public offering, which launched today, lifting the total it hopes to bring in from a previous maximum of $103.5 million up to $108 million. In the offering, the Santa Clara, Calif.-based company said it will offer 7.2 million shares at $15 per share. Si-Bone had previously said it expected to offer […]
Nanobiotix reels in $18.5m tranche from European Investment Bank
Nanobiotix (PAR:NANO.PA) received €16 million ($18.5 million) in the first tranche of a previously-announced non-dilutive loan from the European Investment Bank. The five-year funding deal is designed to support the company’s development of nanoparticle-based cancer therapies. Get the full story at our sister site, Drug Delivery Business News.
Boston Scientific closes $600m Augmenix buyout
Boston Scientific (NYSE:BSX) said yesterday that it closed the $600 million acquisition of Augmenix and its SpaceOar device. The deal for Bedford, Mass.-based Augmenix, announced in September, called for $500 million in up-front cash and another $100 million pegged to sales-based milestones. “This close marks the third completed acquisition in 2018 for the company’s urology & […]
Abbott slips on narrowed earnings guidance
Abbott shares slipped in pre-market trading today after the company narrowed its earnings outlook for the rest of the year, after just meeting both its own forecast and the consensus Wall Street outlook. The Chicago-area healthcare giant’s profits for the three months ended Sept. 30 were off -6.6% at $563 million, or 32¢ per share, […]